Business Wire

SPINE-INNOVATIONS

28.3.2022 13:24:13 CEST | Business Wire | Press release

Share
Spine Innovations Marks Milestone — Over 20,000 ESP Spinal Discs Implanted — as Global Demand Grows

Since its formation as a wholly independent company in late 2020, Spine Innovations has continued to expand sales of its ESP spinal disc replacements, with more than 20,000 prostheses successfully implanted in patients around the world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005394/en/

At the same time, Spine Innovations continues to expand its market reach. The company is now active in 17 countries, including new markets within Europe that opened in 2021. It will expand into Central and South America, including Mexico and Brazil, as well as additional European countries, including Norway and the Netherlands. In 2022, Spine Innovations is also working toward FDA approval to enter the US market.

Spine Innovations’ growth has been energized by operating like a startup and hyper-specializing in total spinal disc replacement and the preservation of natural motion. The company’s Cervical Prosthesis (CP-ESP®) and Lumbar Prosthesis (LP-ESP®) utilize a viscoelastic design — recognized as the latest generation of disc replacement — to mimic the function and range of movements of a natural disc and allow the spine to behave naturally.

Increasing, widespread interest in ESP disc replacements, and their swift acceptance by orthopedic surgeons, neurosurgeons, and patients, highlight the strong desire for products that can restore health and quality of life.

ESP discs combine two titanium end plates with an elastomeric cushion made of polycarbonate urethane. This structure imitates the natural disc, in which bony segments are connected by a spongy disc that provides flexibility while withstanding the pressures of compression and torsion. Specific features of the end plates — short spikes, a rough outer surface, and a coating of hydroxyapatite (HA), which is proven to enhance bone ingrowth — help to ensure stability and bony fixation of the implant over time.

“With the ESP, the patients gain a counter force which is similar to what the natural disc provides and reduces risks of facet pain.” Dr. Svante Berg from Stockholm, Sweden, says Remobilization of the disc space with too much mobility can lead to such side effect.

Pr. Jean Yves Lazennec of Pitie-Salpetriere Hospital in Paris says, “The ESP discs reproduce the natural center of rotation and adapt when the patient is aging.”

The entire team of Spine Innovations is focused on satisfying growing market demand. Sandrine Carle President, says “More and more surgeons are choosing to replace degenerative discs with prostheses that can maintain spinal motion instead of fusing the segment. ESP disc replacements provide that solution by replicating natural disc motion and enabling the entire spine to behave as normally as possible.”

---------------------------------------------

Based in Heimsbrunn (France), Spine Innovations continues to increase market penetration and aims to become a leading actor in the total disc replacement worldwide market with its patented viscoelastic technology used in the ESP discs. To learn more, please visit www.spine-innovations.com and www.esp-disc.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye